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SObjective: Our objective was to analyze the time trend variation of 30-day mortality after lung cancer surgery,
and to quantify the impact of surgeon and hospital volumes over a 5-year period in France.
Methods:We used Epithor, the French national thoracic database and benchmark tool, which catalogues more
than 180,000 procedures of 89 private and public hospitals in France. From January 2005 to December 2010,
19,556 patients who underwent major lung resection (lobectomy, bilobectomy, pneumonectomy) were included
in our study. Multilevel logistic models were designed to investigate the relationship between 30-day mortality
and surgeon (model 1) or hospital (model 2) volumes. The 3 levels considered were the patient, the surgeon, and
the hospital.
Results: From 2005 to 2007, the 30-day mortality of patients who underwent major lung resection averaged
10%, and then decreased until it reached 3.8% in 2010 (P<.0001). A significant decrease in 30-day mortality
was observed over time (P ¼ .0046). During the study period, the mean annual number of procedures per sur-
geon was 46.1 (standard deviation [SD] ¼ 23.6) and per hospital was 97.9 (SD ¼ 50.8). Model 1 showed that
surgeon volume had a significant impact on 30-day mortality (P ¼ .03), whereas model 2 failed to show that
hospital volume influenced 30-day mortality (P ¼ .75).
Conclusions: Since 2007, when France’s first National Cancer Plan became effective, 30-day mortality of pri-
mary lung cancer surgery has decreased and currently measures 3.8%. Lowmortality was correlated with higher
surgeon volume but was not influenced by hospital volume, which cannot be considered a proxy measure for
determining the safety of lung cancer surgery. (J Thorac Cardiovasc Surg 2014;148:841-8)Different lung cancer resection studies designate hospital
and surgeon procedure volumes as easily measurable
indicators of surgical quality.1,2 However, the reality and
soundness of this volume-to-outcome association is still
much debated.3Beside serious concerns regarding the statis-
tical methods used to determine this association,4 it makes
intuitive sense that it should be interpreted cautiously within
the framework of a particular health care system.
The French health care organization involves a multiple-
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The Journal of Thoracic and Caof services and hospitals. Patients in France can navigate
between both private and public facilities and qualify
for reimbursement by the NHI, regardless of which type of
facility provides care. Facilities range from small and some-
what isolated hospitals to tertiary referral centers, such as
university hospitals and Comprehensive Cancer Centers.
Given the complex and varied cancer care available in
France, the government decided to establish quality and
safety requirements to guarantee a consistently high level
of care. The first National Cancer Plan was launched in
2003 and the French National Cancer Institute (INCa)
was created in 2004. This process established a regulatory
framework consisting of dedicated facilities, equipment,
and services, as well as specific standards for multidisci-
plinary approaches, best practice guidelines, and the
qualification of health professionals. Minimum volume
thresholds for radiotherapy, chemotherapy, and cancer
surgery were among the requirements on which the
accreditation of institutions and structure was based.5 For
thoracic cancers, the minimum volume threshold was
fixed at 30 surgical interventions per year per center,
which led to regionalization of cancer surgery services.
Subsequently, 257 health care facilities in France ceased
to be accredited after 2007. This represents 65% of the
facilities that previously performed thoracic cancer surgery
and about 12% of the total number of patients treated for ardiovascular Surgery c Volume 148, Number 3 841
Abbreviations and Acronyms
FSTCVS ¼ French Society of Thoracic and
Cardiovascular Surgery
INCa ¼ French National Cancer Institute
NHI ¼ National Health Insurance
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Sthoracic malignancy in 2005-2007 in France. Therefore,
the French Society of Thoracic and Cardiovascular
Surgery (FSTCVS) decided that a timely investigation of
the practice procedures of lung cancer surgery, over a
period that overlapped with the date on which the legal
measures of France’s first National Cancer Plan became
effective (2007), was necessary.
Thus, the aim of the current study was to explore time
trend variation in 30-day mortality after major primary
lung cancer surgery, and address and quantify the impact
of patient, hospital, and surgeon factors, as well as surgeon
and hospital volumes, in a well-defined national context in
terms of cancer care facilities and processes.
MATERIALS AND METHODS
The Institutional Review Board of the FSTCVS approved the electronic
prospective database used for this study, as well as the study itself (approval
number 2012-1-9-23-6-19-FaPi). Patient consent was obtained before data
entry into the database, and patients were aware that data would be used for
research purposes.
The French National Database Epithor
The FSTCVS database, Epithor (http://www.sfctcv.net/pages/epithor.
php), was created in 2002 as a voluntary initiative of French thoracic sur-
geons. Currently, 89 private and public hospitals contribute to this database
daily, and it includes data on more than 180,000 procedures, which repre-
sents more than 70% of all thoracic surgical procedures performed in
France annually. The database’s characteristics have been described in
detail previously.6-8 All data were analyzed anonymously.
Epithor is a government-approved clinical database funded by INCa for
data quality monitoring. Epithor is also approved by the French National
High Authority for Health (Haute Autorite de Sante), a governmental
agency designed to improve the quality of patient care and to guarantee eq-
uity within the health care system. The software includes functions that
allow participating surgeons to benchmark their activity against national
averages. Regular, external, onsite audits, initiated in 2010, are carried
out to verify the accuracy of data collection.
Hospitals and Surgeons
During the period of data collection, 89 hospitals participated in the
Epithor network; 42 were public hospitals (of which 28 were university
hospitals) and 47 were for-profit or nonprofit private hospitals. Of the
222 participating surgeons, 160 practiced in public hospitals and 62 were
in private practice. As well as thoracic oncology, the whole spectrum of
surgical activities offered by the participating hospitals was recorded:
8 centers also performed lung transplantation, 21 performed esophageal
surgery, 12 performed trauma surgery, and 30 performed vascular surgery
on a regular basis.842 The Journal of Thoracic and Cardiovascular SurgPatients
From January 1, 2005, to December 31, 2010, 122,821 patients were
registered in Epithor, of whom 23,753 had received surgery for lung cancer.
Of those 23,753, we selected 20,640 patients who had undergone a major
procedure for primary lung cancer: lobectomy (n ¼ 16,075; 77.9%), bilo-
bectomy (n ¼ 1166; 5.6%), or pneumonectomy (n ¼ 3399; 16.5%). Sub-
lobar resections were not taken into consideration because a substantial
number had been performed for diagnostic purposes, rather than as poten-
tially curative procedures. Because data entry in certain fields was optional,
a mean 3.3% of values were missing. To enhance the robustness of the re-
sults, we excluded those patients for whom less than 95% of fields had been
completed. Therefore, a group of 19,556 adult patients who had undergone
a major lung resection for primary lung cancer was selected for further
analysis.
Clinical Variables
Baseline demographics, comorbidities, procedures, and outcomes were
recorded. An extra missing value category (referred to as ‘‘unknown’’ in
Table 1) was added for the variables with more than 5% of missing data.
For the other variables, missing data were considered as real missing
data. The patient-related variables that were used were considered as
categorical: age (<55, 56 to 65,>65 years), sex, American Society of Anes-
thesia score (2,3), World Health Organization performance status (2,
3), Medical Research Council dyspnea score (2, 3), and number of
comorbid diseases (0, 1-2, 3). Surgery-related variables included
year of surgery, side of the procedure (left or right), surgical approach
(thoracotomy, video-assisted thoracoscopic surgery), lung resection type
(lobectomy, bilobectomy, and pneumonectomy), technique of lymphade-
nectomy (lymphadenectomy, sampling), and admission acuity (elective,
emergency/urgent). Pathologic staging in accordance with the American
Joint Committee on Cancer Cancer Staging Manual Seventh Edition (stage
I, II, or III), histology (adenocarcinoma, squamous cell carcinoma, other),
and resection margin status (R0, R1-R2) were also reported. Ninety-five
percent of the comorbidities registered in the database were related to 10
major diagnoses: smoking addiction, history of cancer, chronic obstructive
pulmonary disease, arterial hypertension, heart disease, diabetes mellitus,
peripheral vascular disease, obesity, alcoholism, and hyperlipidemia.
Outcome
The end point was 30-day mortality, defined as any patient who died
within 30 days of the date on which the surgical procedure was performed,
regardless of whether the patient was still in hospital or had been dis-
charged. The outcome (30-day individual status) was coded as a binary
variable (alive/dead).
Statistical Analysis
Discrete variables were expressed as counts (%) and continuous vari-
ables were expressed as a mean range, unless otherwise stated. The num-
ber of procedures per surgeon (surgeon volume), or per hospital (hospital
volume), was defined as the number of surgeries registered in Epithor dur-
ing the calendar year. For each hospital, the first year of participation in the
Epithor database was considered as a training period using the software.
Therefore, data that were collected during this period were not used in
the analysis. The number of procedures was treated as a quantitative vari-
able. However, the log linearity assumption was relaxed by introducing a
third order polynomial function of the entered variables into multivariate
models. Time of surgery was also entered.
Multilevel logistic models were designed to investigate the relationship
between 30-day mortality and surgeon volume or hospital volume. A trile-
vel hierarchical structure was considered for analysis: patient, surgeon,
hospital.9 Variables that were significant at a P value<.20 in a bivariate
multilevel analysis were introduced into the models. An iterative general-
ized least squares algorithm was used to run a forward stepwise procedureery c September 2014
TABLE 1. Baseline patients characteristics (n ¼ 19,556)
Variables
All patients
(n ¼ 19,556)
30-day
mortality
(n ¼ 1441) P value*
Age <.0001
<55 y 4026 (20.6) 223 (5.5)
55-65 y 6842 (35.0) 410 (6.0)
65 y 8663 (44.4) 808 (9.3)
Sex <.0001
Male 14,567 (74.5) 1233 (8.5)
Female 4989 (25.5) 208 (4.2)
Priority of surgery <.0001
Elective 19,443 (99,4) 1414 (7.3)
Urgent/emergency 113 (0.6) 27 (23.9)
ASA scorey <.0001
2 14,126 (72.5) 816 (5.8)
3 5362 (27.5) 622 (11.6)
Performance status <.0001
2 17,578 (89.9) 1274 (7.2)
3 161 (0.8) 36 (22.4)
Unknown 1817 (9.3) 131 (7.2)
Dyspnea score <.0001
2 16,453 (84.1) 1184 (7.2)
3 379 (1.9) 64 (16.9)
Unknown 2724 (13.9) 193 (7.1)
Procedure class <.0001
Lobectomy 15,511 (79.3) 954 (6.1)
Bilobectomy 1064 (5.4) 102 (9.6)
Pneumonectomy 2981 (15.2) 385 (12.9)
Surgical approach .0906
Thoracotomy 19,120 (97.8) 1418 (7.4)
VATS 436 (2.2) 23 (5.3)
Side .0295
Right 11,184 (57.5) 863 (60.2)
Left 8271 (42.5) 570 (39.8)
Lymph node dissectionz <.0001
Lymphadenectomy 17,922 (93.9) 1246 (6.9)
Systematic sampling 1175 (6.1) 134 (11.4)
Tumor histologyx <.0001
Adenocarcinoma 8992 (49.8) 571 (6.4)
Squamous cell carcinoma 6026 (33.4) 593 (9.8)
Other 3024 (16.8) 186 (6.1)
Pathologic stage <.0001
IA or IB 8747 (44.7) 433 (4.9)
IIA or IIB 3138 (16.1) 241 (7.7)
IIIA or IIIB 5031 (25.7) 594 (11.8)
Unknown 2640 (13.5) 173 (6.5)
Resection margin statusk <.0001
R0 17,256 (96.5) 1252 (7.3)
R1-R2 618 (3.5) 85 (13.7)
Comorbidities{ <.0001
None 2215 (11.3) 80 (3.6)
1-2 9088 (46.5) 568 (6.2)
3 8252 (42.2) 793 (9.6)
Year of surgery <.0001
2005 2539 (13.0) 298 (11.7)
2006 2706 (13.8) 230 (8.5)
(Continued)
TABLE 1. Continued
Variables
All patients
(n ¼ 19,556)
30-day
mortality
(n ¼ 1441) P value*
2007 3101 (15.9) 289 (9.3)
2008 3452 (17.7) 255 (7.4)
2009 4074 (20.8) 227 (5.6)
2010 3684 (18.8) 142 (3.8)
Type of hospital <.034
Public 14,292 (73.1) 956 (6.7)
Private 5264 (26.9) 485 (9.2)
Data are expressed as numbers and percentages of patients. Because of rounding, per-
centages may not sum to 100. Because of missing data, the regression analysis
included 19,462 patients. ASA, American society of Anesthesiologists; VATS,
video-assisted thoracoscopic surgery. *Multilevel comparison between 30-day dead
or alive status of patients. y68 missing data. z459 missing data. x1514 missing
data. k1682 missing data. {1 missing data.
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Swithin each level. An equivalent Bayesianmodel was then created by incor-
porating prior distributions for each of the parameters in the model, and
performing inference on the resulting posterior distributions. A burn-in
of 5000 iterations was allowed, followed by 100,000 iterations for which
parameter values were stored. The diagnosis (based on chain history, kernel
density plots, and plots of autocorrelation and partial autocorrelation func-
tion) gave no indication that lack of convergence should be suspected. The
odd ratios (ORs) and their 95% confidence intervals were calculated. For
the number of surgeries, the results are expressed as for an increase of
10 procedures. The discriminatory accuracy of the models was quantified
using the C statistic, which provides an estimate of the model’s ability to
discriminate between observed instances of 30-day mortality and sur-
vival.10 A value of 0.5 indicates that the model does not demonstrate any
predictive discrimination, whereas a value of 1 indicates perfect separation.
Multilevel analysis was performed using MLwiN V2.23 software.11 All
other statistical analyses were performed with SAS 9.3 software (SAS
Institute Inc., Cary, NC).RESULTS
The baseline patient characteristics and 30-day mortality
are given in Table 1. During the 6 years of the study period,
there were 1441 deaths (7.4%) among the cohort. The
observed 30-day mortality averaged 10% until 2007, and
then decreased continuously until it reached 3.8% in
2010 (P < .0001) (Table 1). There were 956 deaths
(6.7%) in public hospitals and 485 (9.2%) in private hospi-
tals (P< .034). The 30-day mortality did not statistically
differ when comparing participating centers with regard
to additional surgical activities such as lung transplantation
(7.0% vs 8.4%, P¼ .84), trauma (7.5% vs 7.0%, P¼ .64),
esophageal (7.6% vs 6.8%, P ¼ .71), or vascular (7.6% vs
4.8%,P¼ .051) surgeries. The mean annual number of pro-
cedures per hospital was 97.9 (standard deviation
[SD] ¼ 50.8), with minimum, median, and maximum
values of 1, 93, and 224, respectively. The mean annual
number of procedures was 113.7 (SD¼ 48.4) in public hos-
pitals and 55.0 (SD¼ 26.9) in private hospitals (P<.0001).
On average, a patient is operated on by a surgeon who,
within a year, operated on 46.1 (SD ¼ 23.6) patients, withrdiovascular Surgery c Volume 148, Number 3 843
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respectively. For surgeons working in public hospitals, the
mean annual number of procedures was 46.7
(SD ¼ 24.2); it was 44.3 (SD ¼ 21.9) for surgeons working
in private hospitals (P<.0001). Thirteen hospitals (14.6%)
and 30 surgeons (13.5%) performed 50% of the total num-
ber of procedures in France, and 12.6% of surgeons per-
formed at least 46 procedures per year.
The results of the multilevel logistic regression analysis
are summarized in Table 2. Model 1 highlights 30-day mor-
tality, taking into account annual surgeon volume. Model 2
highlights 30-day mortality, taking into account annual hos-
pital volume. The variables related to patients, type of hos-
pital, and time trends were almost identical for the 2
models. The C statistic obtained for the 2 models was
0.81. Model 1 showed that surgeon volume had a significant
impact on 30-day mortality (P ¼ .03), whereas model 2
showed that hospital volume did not have any impact on
30-day mortality (P ¼ .75).
Model 1 showed that 30-day mortality was strongly influ-
enced by pneumonectomy (OR¼ 2.01), pathologic stage III
(OR ¼ 2.24), and the number of comorbidities greater than
3 (OR¼ 2.51). Model 1 also showed that there was a higher
risk of mortality in private hospitals (OR¼ 1.65; P¼ .0170)
than in public hospitals. The results indicated a significant
decrease in 30-day mortality over time (P ¼ .0046) during
the study period (Figure 1). The significant interaction be-
tween type of hospital and time trends indicated that the
ORs associated with the decrease of 30-day mortality
over time were higher in private hospitals than in public
hospitals (OR¼ 0.85; P¼ .0343). Figure 2 presents the var-
iations in ORs on 30-day mortality over time by surgeon
volume or hospital volume. Figure 2 does not show a statis-
tically significant variation for hospital volume. On the con-
trary, it does show a statistically significant variation for
surgeon volume.
DISCUSSION
This study provides the most current appraisal of 30-day
mortality after primary lung cancer surgery in France. To
date, few studies have had the opportunity to undertake
this kind of investigation from a comprehensive, nation-
wide, population-based dataset. Our study showed that dur-
ing the period 2005-2010, the average 30-day mortality for
patients who had undergonemajor pulmonary resection was
7.4%. This rate is much higher than that reported for the
same period by the United Kingdom’s second National
Thoracic Surgery Activity & Outcomes Report (2.4%).12
It is also higher than the rate reported for the period 2003-
2009 by a US database that assembles the data of 20% of
all hospital discharges from nonfederal facilities
(3.4%).13 Since 2007, 30-day mortality has decreased
continuously in France and in 2010 the value was 3.8%,
reaching the international standards discussed previously.844 The Journal of Thoracic and Cardiovascular SurgThis rate converged in all types of hospitals. The improve-
ment in surgical safety that the present study highlights is
unlikely to be a major consequence of the centralization
of thoracic oncologic surgeries in France. Although 257
health care facilities ceased to be accredited after 2007,
only 6 centers participating in Epithor failed to reach the
minimal threshold of activity and were closed during the
study period. Furthermore, because the redeployment rate
of thoracic surgical activities was 10% to 15% overall, it
had a negligible impact on mortality.
Our study clearly shows that, in the context of the French
health care system, hospital volume is not a proxy measure
for determining the safety of lung cancer surgery. The
volume-outcome relationship is extremely complex. As sug-
gested by Royston and colleagues,14 procedure volume was
first represented as a continuous variable, rather than being
converted into arbitrarily determined categories that amplify
the impact of volume on risk of mortality whenmeasured by
ORs. The cut-off value of the highest volume strata in one
study may be lower than another study’s lowest hospital vol-
ume strata cut-off.15 To describe the nonlinearity present in
the volume-outcome relationship, a regression function
was modeled as a piecewise polynomial that produced a rep-
resentation of the volume-outcome association. A hierarchi-
cal, multilevel modeling technique was used; hospitals and
surgeons were considered/incorporated as random effects,
which adjusted for potentially overdispersed variance esti-
mates.16 The database that was usedwas dedicated to clinical
specialty and capable of understanding and weighting the
clinical significance of the statistical relationship between
volume and mortality.4 The chosen model was excellent
because,with itsC statistic of 0.81, itwas able to discriminate
between observed instances of 30-day death and survival.
Our findings are consistent with those of Birkmeyer and
colleagues,17 who established that the observed association
between hospital volume and operative mortality was
largely mediated by surgeon volume. Our findings are also
fully in line with those of Lien and colleagues,18 who
showed that an inverse volume-outcome relationship exists
for surgeons, but not for hospitals. Having defined volume
categories by tertiles, Lien and colleagues found a signifi-
cantly higher mortality for surgeons who performed less
than 46 procedures per year. Our current study also shows
that better results were obtained for surgeons with an annual
volume of more than 46 procedures (OR< 1) (Figure 2).
This similarity is likely to be coincidental because only ma-
jor procedures were considered in our study, whereas sublo-
bar resections were also taken into account by Lien and
colleagues.18 A meta-analysis of Birkmeyer and Lien’s
studies showed a pooled estimated effect size in favor of
high-volume surgeons. However, this effect did not have sta-
tistical significance andwas very heterogeneous.15 In 2 other
studies, in-hospitalmortality after lobectomywas not signif-
icantly related to the number of procedures performed byery c September 2014
TABLE 2. Multivariate analysis determinants of 30-day mortality after major lung cancer surgery
Variables
Model 1 Model 2
Surgeon level activity Hospital level activity
OR [95% CI] P value OR [95% CI] P value
Age <.0001 <.0001
<55 y 1 1
55-65 y 0.95 [0.79-1.14] 0.95 [0.79-1.14]
65 y 1.53 [1.30-1.82] 1.53 [1.30-1.82]
Sex <.0001 <.0001
Male 1 1
Female 0.63 [0.53-0.74] 0.63 [0.54-0.74]
Priority of surgery .0516 .0516
Elective 1 1
Urgent/emergency 1.69 [0.99-2.86] 1.69 [0.99-2.86]
ASA score <.0001 <.0001
2 1 1
3 1.73 [1.52-1.97] 1.73 [1.51-1.98]
Performance status .0095 .0090
2 1 1
3 2.02 [1.29-3.18] 2.02 [1.29-3.16]
Unknown 1.03 [0.73-1.47] 1.06 [0.74-1.50]
Dyspnea score .0030 .0016
2 1 1
3 1.50 [1.08-2.09] 1.50 [1.08-2.09]
Unknown 0.70 [0.51-0.96] 0.67 [0.49-0.92]
Procedure class <.0001 <.0001
Lobectomy 1 1
Bilobectomy 1.48 [1.17-1.87] 1.49 [1.17-1.88]
Pneumonectomy 2.01 [1.74-2.33] 2.01 [1.74-2.33]
Pathologic stage <.0001 <.0001
IA or IB 1 1
IIA or IIB 1.33 [1.11-1.58] 1.32 [1.11-1.58]
IIIA or IIIB 2.24 [1.94-2.60] 2.24 [1.93-2.59]
Unknown 1.79 [1.44-2.22] 1.79 [1.44-2.22]
Comorbidities <.0001 <.0001
None 1 1
1-2 1.65 [1.28-2.13] 1.67 [1.28-2.17]
3 2.51 [1.93-3.27] 2.54 [1.94-3.33]
Type of hospital .0170 .0206
Public 1 1
Private 1.65 [1.10-2.49] 1.65 [1.08-2.52]
Time trends 0.88 [0.80-0.96] .0046 0.88 [0.80-0.96] .0063
Interaction type of hospital/time trends 0.85 [0.73-0.99] .0343 0.86 [0.74-0.99] .0424
Proc 1 0.92 [0.85-0.99] .0323 0.99 [0.94-1.04] .7488
Proc 2 0.9985 [0.9970-0.9999] .0414 0.9999 [0.9995-1.0004] .9735
Proc 3 1.00004 [1.0000008-1.0000792] .08694 1 [1-1] .5028
The term Proc is the polynomial function of the annual number of procedures. It corresponds to the different coefficients of the polynomial function: Proc 1 for the coefficient of
degree 1, Proc 2 for the coefficient of degree 2, and Proc 3 for the coefficient of degree 3. OR, Odds ratio; CI, confidence interval; ASA, American Society of Anesthesiologists.
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Ssurgeons.19,20 In contrast, our study supports the hypothesis
that the decline in operative mortality is in part due to
increasing surgeon dedication to lung cancer surgery
within hospitals, and even teams. There was an inverse
relationship between surgeon volume and mortality, but no
significant beneficial influence for the regular practice of
other high-risk surgeries. Moreover, it would be unrealistic
to expect lung cancer resections to be primarily undertakenThe Journal of Thoracic and Caby 10% to 15% of the thoracic surgeons currently active in
France. Such an increased workload would have an inverse
effect on surgical safety, as recently suggested by a retro-
spective study from the Mayo Clinic.21
Our study strongly suggests that outcomes measured with
feedback programs, self-assessment capabilities, and
benchmark tools, such as those provided by the Epithor
software, are probably more effective than volume-basedrdiovascular Surgery c Volume 148, Number 3 845
FIGURE 1. Time trends in observed 30-day mortality: public and private hospitals. Over time, we note a decrease in 30-day mortality both in public and
private hospitals with a more significant improvement in the private sector. IC95%, 95% confidence interval.
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Sreferral policies for improving surgical safety. We showed
that the longer a given hospital or surgeon participates in
Epithor, the better the outcome. Because their initial results
were significantly worse than those of the public hospitals,
the improvement in surgical safety was particularly spectac-
ular for the private hospitals, which by 2010 had reached the
national average values for 30-day mortality. Various public
and private US hospitals have already reported the virtuous
process by which a dramatic decline in the rate of postoper-
ative adverse events and 30-day mortality was observed
after the adoption of a National Surgical Quality Improve-
ment Program.22 The Hawthorne effect, which establishesFIGURE 2. Variations in odd ratios (OR) on 30-day mortality by surgeon or ho
hospital volume for 30-day mortality within the Epithor database. The red cur
within the Epithor database. The reference value is 46 procedures per year by
by a given surgeon within Epithor. The lowest OR is estimated for 89 procedure
procedures per year (OR ¼ 1.081).
846 The Journal of Thoracic and Cardiovascular Surgthat the feeling of being observed, or merely participating
in an experiment, can affect individuals’ behavior, might
also be a possible explanation for the improvement in
results.23
There are limitations to our study. Since 2008, after the
application of the legal measures of the National Cancer
Plan, only centers performing more than 30 procedures
per year participated in Epithor, thus decreasing the ability
to find an outcome effect of hospital volume on mortality.
Our study focused on 30-day mortality, which is an imper-
fect surrogate for the risk of mortality attributable to
surgery. Treatment-related mortality should preferablyspital volume. The blue curve symbolizes the modelized odds variation by
ve symbolizes the odds variation by surgeon volume for 30-day mortality
surgeon (OR ¼ 1) corresponding to the mean number of procedures done
s by year (OR ¼ 0.722), whereas the highest OR is estimated for 30 major
ery c September 2014
Falcoz et al General Thoracic Surgeryinclude all deaths that occur as a consequence of a proce-
dure, regardless of the time span between the procedure
and death. For instance, 90-day mortality24 or 6-monthmor-
tality25 has been used for pneumonectomy, after which
physiologic cardiopulmonary impairment due to surgery
can lead to late deaths. Moreover, mortality does not sum
up safety. The overall risk of complications and failure to
rescue (defined as mortality after a complication) are addi-
tional outcomes of interest.13 Safety does not mean quality,
even if these 2 factors are correlatively related. Long-term
survival and resection rate are the primaries objectives of
surgery when analyzed as a potentially curative treatment
in a population-based assessment.26G
T
SCONCLUSIONS
Our findings highlight the overall efficiency of France’s
first National Cancer Plan, implemented in 2007, and its
legal requirements for the practice of surgical oncology.
Encouraging participation in a systematic clinical database
registry is 1 of the keymeasures of this plan, which was well
anticipated by the FSTCVS and the Epithor project. Epithor
stores the best available data (clinical, risk-adjusted and
case mixadjusted, nationally benchmarked and audited
30-day patient outcomes) and provides a more accurate
look at surgical safety than measures based solely on a
volume-outcome relationship. Referring patients, primarily
or solely, to surgeons who perform a large number of proce-
dures should not be advocated because of a possible inverse
effect on surgical safety. Nevertheless, it only makes good
sense that low-volume surgeons with a high observed/ex-
pected mortality ratio should scrutinize their practice proce-
dures and benchmark their results against national averages
that include high-volume surgeons with good outcomes.
They may make improvements in safety, and as a result of
this, learn from mistakes.
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tributions because one is mandatory. Clearly, the legal measure of
the cancer plan for a given department means that you belong to aDr Ara Vaporciyan (Houston, Tex). Dr Falcoz and his col-
leagues have leveraged a new modern multi-institutional databaseCOMMEN
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specifically mortality—associated with the treatment of lung
cancer.
I actually sent Dr Falcoz my questions ahead of time and he
actually already answered 2 out of the 3, so in the interest of letting
the crowd have an opportunity to ask a question, I’m going to go
right to the third question.
I suspect that it is hard, as you identified, to dissect the impact of
a new database and the Hawthorne effect from the impact of a new
National Cancer Plan. However, considering the health care envi-
ronment in the United States, I would imagine that many of us in
this audience are very interested in any evidence that demonstrates
the true value of a national health care plan or any sort of nation-
alization of care. Therefore, this question really focuses on what
you are going to do next. As the new National Cancer Plan in
France gains traction, how are you going to truly examine the
impact of that plan on the delivery of care?
Dr Falcoz. Thank you for your final question, Dr Vaporciyan.
It might be a little bit difficult to answer, because, as you said, it
is a challenge to highlight the individual contribution of the data-
base from the National Cancer Plan, especially as the participation
in our database is a mandatory requirement as one of the measures
of the cancer plan. So it is difficult to dissect between the two con-
database. To conclude, I don’t think it will be possible to clearly
give you an answer of who does what. The effects are mixed.TARYEditorial commentBenjamin D. Kozower, MD, MPHThe volume–outcome relationship has been used as a proxy
measure for quality for more than 3 decades since first pro-
posed by Luft and colleagues1 in 1979. In this issue of the
Journal of Thoracic and Cardiovascular Surgery, Falcoz
and colleagues2 report the results of lung cancer resectionin France captured in the Epithor database. From 2005 to
2010, the database captured the data for almost 20,000
patients undergoing anatomic lung resection for lung
cancer. The most striking result of their report was the
decrease in 30-day mortality from 10% in 2005 to 3.8%
in 2010.
The authors used sophisticated hierarchical logistic
regression models to evaluate the relationship between
procedure volume (both surgeon and hospital) and 30-day
mortality. Rather than categorizing the procedure volume
into arbitrary groups such as quartiles or quintiles, the
authors appropriately modeled volume as a continuous
variable using a polynomial function. The results have
demonstrated that surgeon volume, but not hospital volume,
was associated with 30-day mortality, with a P value<.05.
Although this is statistically significant, it is unclear howery c September 2014
